img

PCI Pharma to buy Pharmaceutical Packaging Professionals

Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) has announced its plan to acquire Australia-based Pharmaceutical Packaging Professionals (PPP). The acquisition of PPP, a leading provider of clinical trial manufacturing, packaging, storage and distribution services, establishes a presence for PCI in Australia, viewed as pivotal to continued growth and expansion in the Asia Pacific region. Australia is one of the leading countries for Phase 1 studies globally, and with this acquisition, PPP’s Phase I offering also enables PCI to better support customers from early phases of clinical development through to commercial launch.

Sharing is caring, show love and share the thread with your friends.

Description

PPP is a recognized leader in clinical trial supply with a comprehensive suite of support services including early clinical phase sterile and non-sterile drug manufacture of investigational medicines, packaging and labeling services for investigational products, as well as logistical services including storage and distribution to global investigational sites. PPP’s expertise supports projects across a range of temperature conditions including controlled room temperature, 2-8°C, -20°C, and -80°C environments, which expands PCI’s existing capabilities in storing, packaging, and shipping Cold Chain products. Experiencing significant demand for its services, PPP is currently undertaking a facility expansion and upgrade to add additional storage and distribution services, labeling and packaging rooms, Grade D manufacturing as well as sterile-fill manufacturing capabilities for Phase II clinical studies.

Tags

Pharmaceutical packaging professionals

References

ppp’s suite of services complements pci’s expansive global portfolio of clinical and commercial services, including clinical and commercial scale drug manufacturing, packaging and labeling of clinical trial medicines, global logistical services to investigational sites and commercial contract packaging services. ppp’s strong market presence with phase i units as well as the company’s geographic reach and experience working with us, european, and asia pacific customers in countries including china, korea, vietnam, sri lanka, taiwan, malaysia, thailand and new zealand, will allow pci to continue to grow its capabilities in the region.

“the addition of ppp is significant for our continued global expansion” stated bill mitchell, president and ceo of pci pharma services. “the asia-pacific region, including australia, is a very attractive and growing segment in the clinical trials market. our customers continue to seek new markets both for execution of their clinical studies as well as partners that can support them through the supply chain.” the addition of ppp will mark pci’s fifth acquisition outside of the u.s. in five years, which underscores pci’s continued commitment to growth and geographic expansion. “this opportunity is part of our next logical phase of geographic expansion and enables us to support our customers in their long term global growth strategies. additionally, ppp’s highly experienced management team has a strong track record in the clinical trials marketplace and we are excited to welcome them to pci.”

View / Download